© 2020 © 2020 Genprex Inc. All Rights Reserved.
Our platform technologies are designed to administer cancer fighting tumor suppressor genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
We are developing our lead product candidate, Oncoprex™ immunogene therapy, to be administered in combination with targeted therapies and immunotherapies for non-small cell lung cancer. Preclinical research indicates that Oncoprex might also be effective in fighting other types of cancer and we are exploring its use in other cancer types.
We are a multidisciplinary team with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
At Genprex, we are committed to pioneering a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
Inside the industry’s quest for its next crowning achievement in oncology.
March 30 marks National Doctors’ Day, an annual holiday when we can all acknowledge and show appreciation for our physicians who help save lives everywhere.
These board additions will enhance the Company’s ability to execute on key corporate initiatives.
These seasoned industry professionals combined with the company’s newly strengthened balance sheet will drive key clinical programs.
We’re passionate about the work we’re doing to revolutionize the fight against cancer, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.